CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: March-18-13
Credit Expiration Date: March-18-14


Program Director 
Kathy S. Albain, MD, FACP
Professor of Medicine
Division of Hematology/Oncology
Loyola University
Chicago Stritch School of Medicine
Director, Breast Clinical Research Program
Director, Thoracic Oncology Program
Cardinal Bernardin Cancer Center
Maywood, IL

Featured Faculty
Clodia Osipo, PhD
Associate Professor
Department of Pathology
Cardinal Bernardin Cancer Center
 Maywood, IL

Ana Maria Gonzalez-Angulo, MD, MSc, FACP
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Larissa A. Korde, MD, MPH
Assistant Professor
Department of Medicine
Division of Oncology
University of Washington
Seattle, WA

Ian Krop, MD, PhD
Assistant Professor, Department of Medicine, Harvard Medical School
Instructor in Medicine, Adult Oncology, Dana-Farber Cancer Institute
Boston, MA

Ann Partridge, MD, MPH
Associate Professor, Department of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Terry Mamounas, MD
Medical Director Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando, FL

Credit Hours



Online Presentation

Program Description

NOTE: This activity was presented live on February 2, 2013. If you received CME credit for attending the live activity or participating in the live webcast, you are not eligible to receive credit for this online release. This symposium concentrated on key results presented at the December 2012 San Antonio Breast Cancer Symposium that have the potential to change standards of practice in breast oncology. The multidisciplinary symposium faculty presented data that will inform practice behavior and improve treatment selection and patient care. Panel discussions (informed by audience interaction with the faculty) complemented the lectures. This activity will help participants understand how the new findings should best be applied to current breast cancer diagnosis and treatment strategies.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists, pathologists, basic scientists, and others interested in the diagnosis and treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss emerging data on and recent advances in the treatment of patients with breast cancer and integrate key findings into clinical practice.


In compliance with ACCME guidelines, Imedex is providing a list of the individuals in a position to control/influence the content of this CME activity and their relevant financial relationships with commercial interests (or absence thereof). Imedex has used a multi-step process to resolve all COI.

Dr. Osipo indicates no relevant financial relationship.

Dr. Gonzalez-Angulo indicates a consultant relationship with Bayer, Celgene, Genentech, and Novartis.

Dr. Albain indicates a financial relationship with Eisai, Genentech/Roche, Genomic Health, Novartis, and Pfizer.

Dr. Korde indicates a financial relationship with Genomic Health.

Dr. Krop indicates a financial relationship with Genentech.

Dr. Partridge indicates no relevant financial relationship.

Dr. Mamounas indicates a speaker/consultant relationship with Celgene, Genentech, and Genomic Health.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Imedex, MCM Education, and Loyola University Chicago.

Imedex is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex designates this enduring material for a maximum of 4.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.

Commercial Support Statements

This activity is supported by educational grants from Genentech, Genomic Health, and AstraZeneca.

Certificate Fee



This CME activity may discuss the investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for all products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patientís medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Imedex, MCM Education, or any of the companies that provided commercial support for this CME activity.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu